FACTOR OF POOR PROGNOSIS IN GERIATRIC ONCOLOGY PATIENTS: POLYPHARMACY AND MANAGEMENT

Yıl 2023, , 215 - 227, 31.05.2023

Emir Avşar , Selda Çelik

https://doi.org/10.52369/togusagbilderg.1094888

Öz

Geriatric oncology patients encounter many comorbidities associated with aging. These comorbidities cause multiple drug use, which is defined as polypharmacy. Polypharmacy complicates the treatment and care process and reduces the quality of life of patients. At the same time, it increases the risk of mortality by negatively affecting the prognosis of cancer. Evaluation and management of such a complex process requires a multidisciplinary approach. In this article; Evaluation of polypharmacy in geriatric oncology patients, complications of polypharmacy, drug-drug and drug-food interactions, its effect on oncological prognosis and effective management of the process are discussed.

Anahtar Kelimeler

geriatrics, oncology, polypharmacy

Geriatrik Onkoloji Hastalarında Kötü Prognoz Etkeni: Polifarmasi ve Yönetimi

Öz

Geriatrik onkoloji hastaları, yaşlanma ile ilişkili birçok komorbidite ile karşılaşmaktadır. Bu
komorbiditeler, çoklu ilaç kullanımı olarak tanımlanan polifarmasiye neden olmaktadır.
Polifarmasi; tedavi ve bakım sürecini zorlaştırarak, hastaların yaşam kalitesini azaltmaktadır.
Aynı zamanda kanserin prognozunu olumsuz etkileyerek mortalite riskini arttırmaktadır. Bu
denli kompleks bir sürecin değerlendirilmesi ve yönetimi, multidisipliner bir yaklaşım
gerektirmektedir. Bu makalede; geriatrik onkoloji hastalarında polifarmasinin
değerlendirilmesi, polifarmasinin komplikasyonları, ilaç-ilaç ve ilaç-besin etkileşimleri,
onkolojik prognoza etkisi ve sürecin etkin bir şekilde yönetilmesi ele alınmıştır.

Anahtar Kelimeler

geriatri, onkoloji, polifarmasi

Kaynakça

• 1. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. Journal of geriatric oncology. 2016;7(5):346-353.
• 2. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clinical interventions in aging. 2008;3(2):383.
• 3. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Jong BMD. The development of polypharmacy. A longitudinal study. Family practice. 2000;17(3):261-267.
• 4. Bikowski RM, Ripsin CM, Lorraine VL. Physician‐patient congruence regarding medication regimens. Journal of the American Geriatrics Society. 2002;49(10):1353- 1357.
• 5. Assari S, Helmi H, Bazargan M. Polypharmacy in African American adults: a national epidemiological study. Pharmacy. 2019;7(2):33.
• 6. Kapucu S. Geriatri Hemşireliği. Ankara: Hipokrat Kitabevi; 2019.
• 7. Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Archives of gerontology and geriatrics. 2018;78:213-220.
• 8. Öztürk Z, Uğraş KG. Yaşlı hastalarda ilaç kullanımı ve polifarmasi. İzmir Tepecik Eğitim ve Araştırma Hastanesi Dergisi. 2017;27(2):103-108.
• 9. Erbay Ö. Yaşlılarda Büyüyen''Polifarmasi''Sorunu: Hemşirelerin Rolü. Türkiye Klinikleri Hemşirelik Bilimleri Dergisi. 2018;10(3):222-227.
• 10. Nightingale G, Skonecki E, Boparai MK. The impact of polypharmacy on patient outcomes in older adults with cancer. The Cancer Journal. 2017;23(4):211-218.
• 11. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. Journal of geriatric oncology.2012;3(3):228-237.
• 12. Kierner KA, Weixler D, Masel EK, Gartner V, Watzke HH. Polypharmacy in the terminal stage of cancer. Supportive Care in Cancer.2016;24(5):2067-2074.
• 13. Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer. Journal of Clinical Oncology.2015;33(13):1453-1459.
• 14. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology.2007;25(14):1824-1831.
• 15. Whitman AM, DeGregory KA, Morris AL, Ramsdale EE. A comprehensive look at polypharmacy and medication screening tools for the older cancer patient. The oncologist. 2016;21(6):723-730.
• 16. Lichtman SM. Polypharmacy: geriatric oncology evaluation should become mainstream. Journal of Clinical Oncology. 2015;33(13):1422-1423.
• 17. Kerry Z. Yaşlılarda doğru ilaç kullanımı. Ege tıp dergisi. 2015:54.
• 18. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674-694.
• 19. Steinman MA, Fick DM. Using wisely: a reminder on the proper use of the American Geriatrics Society Beers Criteria®. Journal of the American Geriatrics Society. 2019;67(4):644-646.
• 20. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age and ageing. 2008;37(6):673-679.
• 21. Blanco‐Reina E, Ariza‐Zafra G, Ocaña‐Riola R, León‐Ortiz M. 2012 American Geriatrics Society Beers Criteria: Enhanced Applicability for Detecting Potentially Inappropriate Medications in E uropean Older Adults? A Comparison with the Screening Tool of Older Person's Potentially Inappropriate Prescriptions. Journal of the American Geriatrics Society. 2014;62(7):1217-1223.
• 22. Oliveira MG, Amorim WW, de Jesus SR, Heine JM, Coqueiro HL, Passos LCS. A comparison of the B eers and STOPP criteria for identifying the use of potentially inappropriate medications among elderly patients in primary care. Journal of evaluation in clinical practice. 2015;21(2):320-325.
• 23. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and ageing. 2014;44(2):213-218.
• 24. O’Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. European Geriatric Medicine. 2010;1(1):45-51.
• 25. Yeşil Y, Cankurtaran M, Kuyumcu ME. Polifarmasi. Klinik Gelişim. 2012;25(3):18-23.
• 26. Beğer T, Suna Erdinçler D, Altıparmak MR. Geriatrik Hasta ve Sorunları. İstanbul: Doyuran Matbaası; 2011.
• 27. Elkin N. Yaşlılarda Polifarmasi ve Akılcı İlaç Kullanımına Aile Hekimliği Yaklaşımı. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2020;(11):279-290.
• 28. Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. Journal of the American Academy of Nurse Practitioners.2005;17(4):123-132.
• 29. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety. 2014;13(1):57–65.
• 30. Frazier SC. Health outcomes and polypharmacy in elderly individuals: An integrated literature review. Journal of Gerontological Nursing. 2005;31(9):4–11.
• 31. Alpert PT, Gatlin T. Polypharmacy in older adults. Home healthcare now. 2015;33(10):524-529.
• 32. Maroñas-Jiménez L, Castellanos-González M, Sanz Bueno J, Vanaclocha Sebastián F. Erosiones y úlceras acrales: manifestación precoz de toxicidad aguda grave por metrotexato. Actas Dermo-Sifiliográficas. 2014;105(3):322-323.
• 33. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. European journal of clinical pharmacology. 1992;42(2):121-125.
• 34. Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. Journal of Antimicrobial Chemotherapy. 2006;58(1):228-230.
• 35. Koerber H, Gross WL, Iven H. Do steroids influence low dose methotrexate pharmacokinetics?. The Journal of rheumatology. 1994;21(6):1170-1172.
• 36. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Critical reviews in oncology/hematology. 2003;48(2):133-143.
• 37. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. The Lancet Neurology. 2003;2(7):404-409.
• 38. Bermúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. Journal of Pediatric Hematology/Oncology. 2005;27(7):389-392.
• 39. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer treatment reviews. 2004;30(2):181-191.
• 40. Shah SR, Martin R, Dowell JE, Ussery SMG. Comparison of the 5‐Fluorouracil‐Warfarin and Capecitabine‐Warfarin Drug Interactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2010;30(12):1259-1265.
• 41. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016:354.
• 42. Levêque D, Becker G, Bilger K, Natarajan-Amé S. Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clinical Pharmacokinetics. 2020;59(7):849-856.
• 43. Ikeda H, Murakami T, Takano M, Usui T, Kihira K. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. British journal of clinical pharmacology. 2005;59(5):593-597.
• 44. Couderc LJ, Stelianides S, Frachon I, Stern M, Epardeau B, Baumelou E et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Respiratory medicine. 1999;93(1):65-68.
• 45. Johnson EJ, MacGowan AP, Potter MN, Stockley RJ, White LO, Slade RR, Reeves DS. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy. 1990;25(5):837-842.
• 46. Giunta G. Warfarin–5-FU interactions. Annals of oncology. 2006;17(1):176.
• 47. Van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Annals of oncology. 2001;22(10):2334-2341.
• 48. de Jonge ME, Huitema A.D, van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer chemotherapy and pharmacology. 2005;55(5):507-510.
• 49. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. The lancet oncology. 2011;12(13):1249-1257.
• 50. Nightingale G, Hajjar E, Guo K, Komura S, Urnoski E, Sendecki J et al. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer. Journal of geriatric oncology. 2015;6(5):411-417.
• 51. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side‐effect management 1. Journal of clinical pharmacy and therapeutics. 2007;32(2):169-175.
• 52. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. Journal of oncology practice. 2017;13(7):613-622.
• 53. Chen LJ, Nguyen TNM, Chang-Claude J, Hoffmeister M, Brenner H, Schöttker B. Association of polypharmacy with colorectal cancer survival among older patients. The oncologist. 2021;26(12):2170-2180.
• 54. Jørgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. Journal of geriatric oncology. 2020;11(4):593-602.
• 55. Loh KP, Soto Pérez de Celis E, Duberstein PR, Culakova E, Epstein RM, Xu H et al. Patient and caregiver agreement on prognosis estimates for older adults with advanced cancer. Cancer. 2021;127(1):149-159.
• 56. Mangoni AA, Jackson SH. Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British journal of clinical pharmacology. 2004;57(1):6-14.
• 57. Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E. Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Supportive Care in Cancer. 2018;26(12):4105-4113.
• 58. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA internal medicine. 2015;175(5):827-834.
• 59. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. Journal of clinical oncology. 2007;25(14):1832-1843.
• 60. Puts MT, Costa-Lima B, Monette J, Girre V, Wolfson C, Batist G, Bergman H. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they?. Drugs & aging. 2009;26(6):519-536.
• 61. Kaya H, Turan N, Çulha Y, Aydın GÖ. Yaşlı Bireylerde İlaç Yönetiminde Hemşirenin Rolü. JAREN/Hemşirelik Akademik Araştırma Dergisi. 2018;4(2):120-126.
• 62. Karadakovan A. Yaşlı sağlığı ve bakım. Ankara: Akademisyen Kitabevi; 2014.